Biolegend Inc. Reagents and Kits for the Critical Care Medicine Department (CCMD)
Looking for contract opportunity help?
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
General Information
- Contract Opportunity Type: Presolicitation (Original)
- Original Published Date: Jun 13, 2024 09:47 pm EDT
- Original Response Date: Jun 26, 2024 06:30 am EDT
- Inactive Policy: Manual
- Original Inactive Date: Jun 27, 2024
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code: 6505 - DRUGS AND BIOLOGICALS
- NAICS Code:
- 325414 - Biological Product (except Diagnostic) Manufacturing
- Place of Performance: Bethesda , MD 20892USA
Description
Title
Biolegend Inc. Reagents and Kits for the Critical Care Medicine Department (CCMD)
- Product Service Code: 6505
- NAICS Code: 325414
- Place of Performance:
Bethesda, MD 20892 USA
POTS: 24-009410
Description
This is a notice of intent, NOT a request for a quotation. A solicitation document will NOT be issued, and quotations will NOT be requested.
The National Institutes of Health (NIH) intends to award a fixed price purchase order to Biolegend, Inc. located in San Diego, CA 92121 on a sole source basis for the procurement reagents and kits for the Critical Care Medicine Department (CCMD).
Description/Part #/ Qty
TotalSeq™-C Human Universal Cocktail, V1.0/399905/4
The Critical Care Medicine Department is studying the natural history of lung injury and inflammation post COVID19 infection to assess the mechanisms of the injury and the potential treatment options. The TotalSeq™-C Human Universal Cocktail 5T, is used for single cell sequencing in 10X Genomics equipment currently located in CCMD.
Biolegend Inc., is the sole manufacturer and trademark holder of the proprietary antibody TotalSeq™-C Human Universal Cocktail 5T.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. The total dollar value of this requirement shall not exceed the Simplified Acquisition Threshold (SAT), $250,.000.00.
Interested parties may submit capability statements in response to this posting by the closing date for review. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.
Comments to this announcement, referencing this posting number, may be submitted to the Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Shasheshe Goolsby, Lead Contract Specialist, shasheshe.goolsby@nih.gov by June 26, 6:30AM EST.
*** Please send your capability statements ONLY. This IS NOT a request for proposal. ***
Attachments/Links
Contact Information
Contracting Office Address
- 6707 DEMOCRACY BLVD, SUITE 106
- BETHESDA , MD 20892
- USA
Primary Point of Contact
- Shasheshe Goolsby
- shasheshe.goolsby@nih.gov
- Phone Number 3018274879
Secondary Point of Contact
History
- Jun 27, 2024 11:55 pm EDTPresolicitation (Original)